Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17170-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#17170-1-AP, RRID:AB_2264448
- Product name
- IARS2 antibody
- Antibody type
- Polyclonal
- Description
- KD/KO validated IARS2 antibody (Cat. #17170-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references High dose isoleucine stabilizes nuclear PTEN to suppress the proliferation of lung cancer.
Mitochondrial Threonyl-tRNA Synthetase TARS2 Is Required for Threonine-Sensitive mTORC1 Activation.
IARS2 regulates proliferation, migration, and angiogenesis of human umbilical vein endothelial cells.
The Oncogene IARS2 Promotes Non-small Cell Lung Cancer Tumorigenesis by Activating the AKT/MTOR Pathway.
Wang H, Chen S, Kang W, Ding B, Cui S, Zhou L, Zhang N, Luo H, Wang M, Zhang F, Zhao Z, Guo Z, Wang C, Li L, Wang Z, Chen X, Wang Y
Discover oncology 2023 Feb 23;14(1):25
Discover oncology 2023 Feb 23;14(1):25
Mitochondrial Threonyl-tRNA Synthetase TARS2 Is Required for Threonine-Sensitive mTORC1 Activation.
Kim SH, Choi JH, Wang P, Go CD, Hesketh GG, Gingras AC, Jafarnejad SM, Sonenberg N
Molecular cell 2021 Jan 21;81(2):398-407.e4
Molecular cell 2021 Jan 21;81(2):398-407.e4
IARS2 regulates proliferation, migration, and angiogenesis of human umbilical vein endothelial cells.
Yu YM, Xu L, Li HR, Zhang TQ, Qian G, Li LF, Wang MH
Revista da Associacao Medica Brasileira (1992) 2021 Apr;67(4):555-560
Revista da Associacao Medica Brasileira (1992) 2021 Apr;67(4):555-560
The Oncogene IARS2 Promotes Non-small Cell Lung Cancer Tumorigenesis by Activating the AKT/MTOR Pathway.
Di X, Jin X, Ma H, Wang R, Cong S, Tian C, Liu J, Zhao M, Li R, Wang K
Frontiers in oncology 2019;9:393
Frontiers in oncology 2019;9:393
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 17170-1-AP(IARS2 antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of HepG2 cells, using IARS2 antibody 17170-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human brain using 17170-1-AP(IARS2 antibody) at dilution of 1:100 (under 10x lens)
- Sample type
- tissue
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human brain using 17170-1-AP(IARS2 antibody) at dilution of 1:100 (under 40x lens)
- Sample type
- tissue